Comparative Pharmacology
Head-to-head clinical analysis: GEMCITABINE versus SIKLOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEMCITABINE versus SIKLOS.
GEMCITABINE vs SIKLOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gemcitabine is a nucleoside analog (2',2'-difluorodeoxycytidine) that is phosphorylated intracellularly to active diphosphate (dFdCDP) and triphosphate (dFdCTP) metabolites. dFdCDP inhibits ribonucleotide reductase, reducing deoxynucleotide pools for DNA synthesis. dFdCTP competes with deoxycytidine triphosphate for incorporation into DNA, causing masked chain termination and inhibiting DNA polymerase and repair.
Hydroxyurea inhibits ribonucleotide reductase, reducing the synthesis of deoxyribonucleotides and thereby decreasing DNA synthesis. In sickle cell disease, it increases fetal hemoglobin (HbF) levels, which inhibits sickling of red blood cells.
1000-1250 mg/m² intravenously over 30 minutes on days 1 and 8 of a 21-day cycle.
100–200 mg/kg/day orally in two divided doses, not to exceed 200 mg/kg/day.
None Documented
None Documented
Clinical Note
moderateGemcitabine + Digoxin
"Gemcitabine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateGemcitabine + Digitoxin
"Gemcitabine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateGemcitabine + Deslanoside
"Gemcitabine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateGemcitabine + Acetyldigitoxin
"Gemcitabine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life for gemcitabine is 42-94 minutes (mean ~57 min) in plasma; for its metabolite dFdU, the half-life is 14-74 hours (mean ~40 h), which accumulates with repeated dosing and may contribute to prolonged systemic exposure.
Terminal elimination half-life is 2-5 hours in adults; shorter in children (1-2 hours). Clinical context: requires thrice-daily dosing to maintain therapeutic concentrations; longer half-life in hepatic impairment (up to 10 hours).
Primarily renal: ~92-98% of the dose excreted in urine, with <10% as unchanged gemcitabine and the majority as the inactive metabolite 2',2'-difluorodeoxyuridine (dFdU). Fecal excretion is minimal (<1%).
Primarily hepatic metabolism via CYP3A4; renal excretion of metabolites accounts for approximately 70-80% of the dose, with <1% excreted unchanged in urine. Fecal excretion is minor (<5%).
Category D/X
Category C
Antimetabolite
Antimetabolite